BARCA, LUCIA
 Distribuzione geografica
Continente #
EU - Europa 26.618
NA - Nord America 566
AS - Asia 113
OC - Oceania 2
AF - Africa 1
Totale 27.300
Nazione #
IT - Italia 26.409
US - Stati Uniti d'America 566
CN - Cina 76
SE - Svezia 67
DE - Germania 51
UA - Ucraina 42
GB - Regno Unito 14
FI - Finlandia 13
VN - Vietnam 12
IN - India 8
BE - Belgio 6
HK - Hong Kong 6
FR - Francia 4
RO - Romania 4
SG - Singapore 4
AU - Australia 2
ES - Italia 2
RS - Serbia 2
RU - Federazione Russa 2
TH - Thailandia 2
TR - Turchia 2
EG - Egitto 1
IL - Israele 1
JO - Giordania 1
KR - Corea 1
NL - Olanda 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 27.300
Città #
Cagliari 26.317
Chandler 86
Fairfield 58
Ann Arbor 53
Nyköping 51
Ashburn 35
Dearborn 34
Woodbridge 31
Houston 27
Wilmington 27
New York 20
Seattle 20
Shanghai 18
Cambridge 16
Jacksonville 16
Nanjing 15
Boston 13
Dong Ket 12
Boardman 11
Beijing 10
San Mateo 9
Helsinki 7
Brussels 6
Falls Church 6
Guangzhou 6
Hong Kong 6
Rome 6
Santadi 6
Washington 6
Atlanta 5
Leawood 5
Sìnnai 5
Carpi 4
Nanchang 4
Sassari 4
Brescia 3
Jiaxing 3
Norwalk 3
Pune 3
Quartu Sant'elena 3
San Diego 3
Taizhou 3
Tianjin 3
Bengaluru 2
Bitonto 2
Cabras 2
Changsha 2
Frignano 2
Jinan 2
Kunming 2
Martin de la Jara 2
Mountain View 2
Redmond 2
Zonguldak 2
Aachen 1
Amsterdam 1
Augusta 1
Azor 1
Belgrade 1
Bratislava 1
Catania 1
Chiaramonti 1
Chongqing 1
Dolianova 1
Dolovo 1
Hebei 1
Hyderabad 1
Longmont 1
Madison 1
Mascalucia 1
Mengen 1
Monmouth Junction 1
Munich 1
Newcastle upon Tyne 1
Ningbo 1
Phoenix 1
Radeberg 1
Redwood City 1
Salerno 1
San Gavino Monreale 1
San Sperate 1
Shenyang 1
Simi Valley 1
Sohag 1
Sydney 1
Trebaseleghe 1
Wandsworth 1
Wuhan 1
York 1
Totale 27.036
Nome #
Exploring the Role of Killer Cell Immunoglobulin-Like Receptors and Their HLA Class I Ligands in Autoimmune Hepatitis 4.053
Killer cell immunoglobulin-like receptors and their HLA class I ligands in autoimmune hepatitis: a possible pathogenetic role ? 3.003
Role of interferon lambda 4 and ALT levels in optimising treatment of HCV for patients with low-stage fibrosis 2.635
Combination of IFNL4 polymorphisms and ALT reduction at 4 week of treatment with PEG IFN and Ribavirin is a new selection tool to optimize antiviral treatment allocation in HCV patients with low stage fibrosis 2.420
Bone mass preservation with high-dose cholecalciferol and dietary calcium in HIV patients following antiretroviral therapy. Is it possible? 2.385
FATTORI IMPLICATI NELLA STORIA NATURALE DELL'INFEZIONE DA VIRUS DELTA:IL RUOLO DEGLI INTERFERONI 2.293
IMPACT OF KILLER-CELL IMMUNOGLOBULIN-LIKE RECEPTORS ON PROGRESSION OF HEPATOCELLULAR CARCINOMA 2.162
Role of natural killercells receptors on the development and progression of hepatocellularcarcinoma 2.140
INFLUENZA DEI POLIMORFISMI DELL’INTERFERONE LAMBDA NELLA STORIA NATURALE DELLA INFEZIONE CRONICA DA HBV: COINCIDENZA O REALTÀ? 2.136
Intraoperative parathyroid hormone (PTH) testing in patients with primary hyperparathyroidism and PTH levels in the normal range 2.057
Dynamics of TT virus infection in a cohort of HCV-infected patients achieving sustained virologic responce after treatment with direct-acting antivirals 1.904
HCV treatment in Sardinian HIV-HCV coinfected patients: a real-life perspective study on safety, efficacy, and immune reconstitution 167
Totale 27.355
Categoria #
all - tutte 30.779
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.779


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019147 0 0 0 0 0 0 0 0 0 0 67 80
2019/20207.018 270 135 20 65 2.726 2.075 1.052 152 94 105 94 230
2020/20219.685 226 417 369 3.196 1.765 1.037 554 551 288 577 478 227
2021/20221.450 222 118 39 118 172 84 52 49 171 164 182 79
2022/20231.802 131 287 317 166 138 141 65 126 110 109 137 75
2023/20241.433 70 144 76 139 153 270 251 132 91 99 8 0
Totale 27.355